Exposure to environmental particulate matter ≤ 10 μm in diameter (PM 10) is associated with an increased risk for giant cell arteritis, particularly in older individuals aged ≥ 70 years and those with ...

Recent advances in the study of inflammatory vasculitides have underscored the complexity of both giant cell arteritis (GCA) and Takayasu arteritis (TAK). Research has increasingly revealed the ...

SHREVEPORT, La. -- Patients who have a condition called giant cell arteritis are concerned it could be going undiagnosed. Dr. Robert Goodman of The Arthritis and Rheumatology Clinic in Shreveport ...

SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck. Symptoms include, head ...

Please provide your email address to receive an email when new articles are posted on . Upadacitinib bested placebo for achieving remission at 52 weeks in GCA, a new indication for the drug. The ...

The most dramatic symptoms of GCA (for example, visual loss) result directly from the inflammation of the large- and medium-sized cranial vessels. Other symptoms appear nonspecific and are related to ...

(RTTNews) - AbbVie Inc. (ABBV) Thursday announced positive results from SELECT-GCA Phase 3 of Upadacitinib 15 mg, once daily in combination with a 26-week steroid taper regimen in adults with giant ...

Mortality rates among patients with giant cell arteritis (GCA) in Canada's Ontario province rose by 15% from 2000 to 2018, a new study found, even as the general population saw declines in overall ...

For patients with giant cell arteritis (GCA), a higher total vascular score (TVS) based on 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging at diagnosis is associated with a ...

Findings showed 46% of patients who received upadacitinib 15mg achieved sustained remission at week 52 compared with 29% of patients who received placebo. Patients with giant cell arteritis (GCA) who ...